Good prescribing: better systems and prescribers needed

Citation for published version:

Digital Object Identifier (DOI):

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
CMAJ : Canadian Medical Association Journal

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Good prescribing: better systems and prescribers needed

Simon Maxwell MD PhD

Previously published at www.cmaj.ca

From the Clinical Pharmacology Unit, University of Edinburgh, Clinical Research Centre, Western General Hospital, Edinburgh, UK


Prescribing is at the core of the therapeutic efforts made by doctors both in hospital and in primary care. Observational studies have highlighted the challenges to delivering high-quality clinical outcomes for patients in both settings. Avoidable adverse effects of medicines are a common cause of admission to hospital and occur frequently in those who are admitted. Medication errors are also common. A recent prospective observational study in the United Kingdom showed that 10% of prescriptions in hospital contained errors and that senior doctors were culpable almost as frequently as recent graduates. Patients are often denied some of the most evidence-based treatments while being maintained on those that are unnecessary. Finally, rates of adherence to long-term therapy are often low, which calls into question the confidence that patients have in their physicians and the medicines they prescribe.

For prescribing to be of high quality, it should be safe, effective, cost-effective and patient-centred. Perhaps we should not be surprised that it often falls short of this ideal. Prescribing is a complex task that requires diagnostic skills, knowledge of medicines, communication skills, an understanding of the principles of clinical pharmacology, appreciation of risk and uncertainty and, ideally, experience. The demands placed on prescribers are also rising because of the increased choice of medicines available, expanding indications for drug treatment, greater complexity of treatment regimens and associated polypharmacy, and a growing elderly patient population. The other major challenge is the pace of change in therapeutics. New evidence on effectiveness, emerging safety signals and changing costs means that what is considered good prescribing today may not necessarily be so in a year.

The sheer volume of prescriptions means that some poor outcomes are inevitable. However, every effort should be made to improve quality and minimize risk. Two research articles published recently in CMAJ illustrate the difficulties in achieving such improvements. In the first, Shojania and colleagues report on their investigation into the efficacy of a collaborative model involving family physicians and community pharmacists in improving the care of patients with dyslipidemia. The pharmacists counselled patients about their medications and lifestyle changes, requested laboratory tests, monitored the effectiveness and safety of medications and patients’ adherence to treatment, and adjusted medication dosages. Compared with patients assigned to receive usual care (presumably reflecting a more cautious or cost-effective approach of the pharmacists), patients in the collaborative care group were much less likely to receive high-potency statins, had more visits with health care professionals and more laboratory tests, and were more likely to have their lipid-lowering treatment changed and to report lifestyle changes. After a year of follow-up, the mean reduction in low-density lipoprotein (LDL) cholesterol in the collaborative care group was small and only slightly better than the reduction in the usual care group (crude difference $-0.2 \text{ mmol/L}$; adjusted difference $-0.05 \text{ mmol/L}$).

In the second article, Villeneuve and colleagues report on their investigation into the efficacy of a collaborative model involving family physicians and community pharmacists in improving the care of patients with dyslipidemia. The pharmacists counselled patients about their medications and lifestyle changes, requested laboratory tests, monitored the effectiveness and safety of medications and patients’ adherence to treatment, and adjusted medication dosages. Compared with patients assigned to receive usual care (presumably reflecting a more cautious or cost-effective approach of the pharmacists), patients in the collaborative care group were much less likely to receive high-potency statins, had more visits with health care professionals and more laboratory tests, and were more likely to have their lipid-lowering treatment changed and to report lifestyle changes. After a year of follow-up, the mean reduction in low-density lipoprotein (LDL) cholesterol in the collaborative care group was small and only slightly better than the reduction in the usual care group (crude difference $-0.2 \text{ mmol/L}$; adjusted difference $-0.05 \text{ mmol/L}$).

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.

© 2010 Canadian Medical Association or its licensors

540

CMAJ • APRIL 6, 2010 • 182(6)
Taken together, these articles imply that achieving meaningful improvements in prescribing behaviour is difficult. However, any pessimism should be mitigated by the apparent success of the pharmaceutical industry. With a careful and well-funded combination of attractive literature, development of personal relationships, product placement, and educational events often involving subtle support for new products by key opinion leaders, the pharmaceutical industry very effectively manages to change prescribing habits. As Moynihan put it, “Food, flattery and friendship are all powerful tools of persuasion, particularly when combined.” But the industry is also methodical in its approach: drug representatives get to know their physicians, analyze what they do and use this as the basis for seeking change.\(^1\)

Could publicly funded health care systems be as effective as the pharmaceutical industry? Although they cannot flex the same financial muscle, they do have power, as employers and regulators, to exert their own influence on individual prescribers and the environments in which they work.

Prescribers could be better equipped to confront the pressures they face. First, and foremost, all doctors need to start with their careers a firm understanding of clinical pharmacology, the science that underpins rational use of medicines. This will enable them to critically evaluate the many sources of information they get and respond to change. Medical schools should respond to the widespread concerns about adverse medication events by making competence in prescribing a prominent feature of their curricula and assessments. This education process should continue into the postgraduate years, with protected time to attend professional development programs led by the service rather than by the pharmaceutical industry. Prescribers are influenced by meaningful feedback on quality markers, such as antibiotic use,\(^12\) and should be given information that allows them to reflect on and change their current prescribing practices. Clinical units should audit adverse medication events at regular intervals.

Health care systems could do more to improve matters. The development of formularies can change prescribing practice, especially if they are locally owned and supported.\(^13\) Incentive schemes are also an effective means of promoting the use of evidence-based and cost-effective prescribing.\(^14\) The checking and review of prescriptions by prescribing colleagues and other professionals such as nurses and pharmacists could be embedded into routine practice. Pharmacists not only prevent errors reaching patients\(^3\) but can also support the prescribing process by educating patients and improving clinical outcomes.\(^3,13\) Notwithstanding the reservations that

**Competing interests:** None declared.

**REFERENCES**


**Correspondence to:** Prof. Simon Maxwell, Clinical Pharmacology Unit, University of Edinburgh, Clinical Research Centre, Western General Hospital, Edinburgh EH4 2XU, UK; s.maxwell@ed.ac.uk